Masimo Co. (NASDAQ:MASI – Get Rating) has received an average recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $179.60.
A number of research firms have recently weighed in on MASI. Wolfe Research began coverage on Masimo in a report on Tuesday, April 5th. They set a “market perform” rating and a $160.00 price target on the stock. StockNews.com raised Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, May 17th. Piper Sandler dropped their target price on Masimo from $160.00 to $130.00 in a report on Wednesday, May 4th. Stifel Nicolaus dropped their target price on Masimo from $175.00 to $150.00 in a report on Wednesday, May 4th. Finally, TheStreet cut Masimo from a “b-” rating to a “c+” rating in a report on Tuesday, February 22nd.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley lifted its stake in Masimo by 82.0% in the 3rd quarter. Morgan Stanley now owns 159,486 shares of the medical equipment provider’s stock worth $43,175,000 after acquiring an additional 71,836 shares in the last quarter. Royal Bank of Canada lifted its stake in Masimo by 4.4% in the 3rd quarter. Royal Bank of Canada now owns 45,154 shares of the medical equipment provider’s stock worth $12,225,000 after acquiring an additional 1,890 shares in the last quarter. LPL Financial LLC lifted its stake in Masimo by 8.0% in the 3rd quarter. LPL Financial LLC now owns 29,006 shares of the medical equipment provider’s stock worth $7,852,000 after acquiring an additional 2,152 shares in the last quarter. Wellington Management Group LLP lifted its stake in Masimo by 80.5% in the 3rd quarter. Wellington Management Group LLP now owns 613,664 shares of the medical equipment provider’s stock worth $166,125,000 after acquiring an additional 273,728 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Masimo during the 3rd quarter worth about $1,914,000. 92.03% of the stock is owned by institutional investors and hedge funds.
Masimo (NASDAQ:MASI – Get Rating) last issued its earnings results on Tuesday, May 3rd. The medical equipment provider reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.01. The firm had revenue of $304.24 million for the quarter, compared to analysts’ expectations of $308.04 million. Masimo had a net margin of 17.91% and a return on equity of 15.46%. Masimo’s revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the company posted $0.90 earnings per share. On average, research analysts anticipate that Masimo will post 4.61 earnings per share for the current year.
About Masimo (Get Rating)
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
- Get a free copy of the StockNews.com research report on Masimo (MASI)
- MarketBeat Podcast: How To Navigate The Market Downturn Like A Pro
- Cracks Form In Adobe’s Growth Outlook
- Chewy Stock is Not All Bark and No Bite
- Two High Yields The Insiders Are Buying
- PEG Ratio Pegs These 3 Stocks as Long-Term Buys
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.